Executives On The Move
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: Jubilant, Mithra And More
Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.
Executives On The Move: Oncorus, Orphazyme and More
Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.
Executives On The Move: Kintor, Nexus and More
Recent executive moves in the industry include C-suite changes at Kintor Pharmaceutical and Antisense Therapeutics. Meanwhile, new directors were appointed at Nexus Pharmaceuticals and BiomX.
Executives On The Move: Grifols, Voyager and More
Recent executive moves in the industry include C-suite changes at Grifols and Zevra Therapeutics. Meanwhile, new directors were appointed at Voyager Therapeutics and Transgene.
Executives On The Move: Adagene, Provention and More
Recent executive changes in the industry include C-suite changes at Adagene and AstraZeneca. Meanwhile, new directors were appointed at Provention Bio and WPD Pharmaceuticals.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: BMS names new CEO; Novartis culls pipeline; AstraZeneca taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.
Executives On The Move: Ocuphire, Vivanza and More
Recent executive moves in the industry include C-suite changes at Ocuphire Pharma and Race Oncology. Meanwhile, new directors were appointed at Vivanza Biosciences and Cue Biopharma.
Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum
Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.
Executives On The Move: Kintor, Poseida and More
Recent executive moves in the industry include C-suite changes at Kintor Pharmaceutical and BioVaxys Technology. Meanwhile, new directors were appointed Poseida Therapeutics and NeuroNascent.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: partial US clinical hold for evobrutinib; Takeda pulls back early AAV gene therapy and rare hematology research; Lilly and Novo shape up for obesity battle; Vir’s new CEO talks to Scrip; and the declining state of pain R&D.
Executives On The Move: Zymeworks, Novan and More
Recent executive moves in the industry include C-suite changes at NervGen Pharma and Novan. Meanwhile, new directors were appointed at Zymeworks and Mirum Pharmaceuticals.
Executives On The Move: Heron Therapeutics, Achieve Life Sciences and More
Recent executive changes in the industry include C-suite changes at Inozyme Pharma and Heron Therapeutics. Meanwhile, new directors were appointed Achieve Life Sciences and Entrada Therapeutics.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.